Neurology Minute

Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis.
 Show citation: 
Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2

Dr. Zohaib Siddiqi shares clinical pearls on negative myoclonus.

Dr. Margarita Fedorova discusses the use of troriluzole for spinocerebellar ataxia. 
Show citations: 
https://www.neurology.org/doi/10.1212/WNL.0000000000209018 
https://clinicaltrials.gov/study/NCT06034886 
https://clinicaltrials.gov/study/NCT02960893

Drs. Paul Crane, Fiifi Duodu, and Malya Sahu discuss neuroimmunology and multiple sclerosis diagnosis in Africa, including challenges and efforts to improve care. 
Show citation: 
Sahu M, Chomba M, Duodu F, Diaz MM, Sokhi D, Saylor D. The Current State of Diagnostics for Neuroimmunological Disorders in Africa. J Cent Nerv Syst Dis. 2025;17:11795735251385319. Published 2025 Nov 19. doi:10.1177/11795735251385319

Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions. 
Show citation: 
Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:10.1212/WNL.0000000000218284